Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | IKEMA: isatuximab, carfilzomib and dexamethasone in RRMM

Roman Hajek • 10 Jun 2021
ASCO 2021
Multiple Myeloma Antibodies Carfilzomib Dexamethasone Isatuximab Lenalidomide
IKEMA

Roman Hajek, MD, PhD, University Hospital Ostrava, Ostrava, Czech Republic, outlines the findings of the Phase III IKEMA trial (NCT03275285), which assessed the efficacy and safety of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. 302 patients with prior treatment were enrolled and treated with isatuximab, carfilzomib and dexamethasone significantly improved progression-free survival (PFS) compared with carfilzomib and dexamethasone alone. A significant increase in minimal residual disease (MRD) negativity was additionally reported, as well as an acceptable safety profile. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Roman Hajek

3:22
ANCHOR: melphalan flufenamide in R/R myeloma
Roman Hajek • 10 Jun 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals